Ceftazidime in patients with impaired renal function. Studies on pharmacokinetics and nephrotoxicity.

J Chemother

Department of Pharmacology and Toxicology, Faculty of Medicine, University of Trondheim, Trondheim, Norway.

Published: July 1989

Download full-text PDF

Source

Publication Analysis

Top Keywords

ceftazidime patients
4
patients impaired
4
impaired renal
4
renal function
4
function studies
4
studies pharmacokinetics
4
pharmacokinetics nephrotoxicity
4
ceftazidime
1
impaired
1
renal
1

Similar Publications

We report a first case of ceftazidime-resistant pediatric melioidosis involving a previously healthy seven-year-old boy who presented with right lobar pneumonia complicated with a 5-cm lung abscess. Ceftazidime was initiated on Day-6 of admission when (ceftazidime-susceptible, minimum inhibitory concentration [MIC] 1.0 mcg/mL) was isolated from blood.

View Article and Find Full Text PDF

Background: Carbapenem-resistant urinary tract infections (CR-UTIs) are a major global health threat. Many factors contribute to the increasing incidence of CR-UTI. Owing to the limited availability of treatment options, CR-UTIs are highly challenging to treat.

View Article and Find Full Text PDF

Objective: This study aimed to analyze the antimicrobial resistance profiles, clinical characteristics and risk factors of bacteremia caused by complex (ECC) strains.

Methods: We retrospectively collected clinical data from patients diagnosed with ECC bacteremia between 2013 and 2022 in a tertiary hospital in Jiangsu. Subgroup analyses were performed based on multidrug resistance (MDR), nosocomial acquisition, polymicrobial bacteremia, and mortality.

View Article and Find Full Text PDF

Objectives: This study aimed to describe the epidemiology and antimicrobial susceptibility patterns of gram-negative pathogens in Brazil from 2018 to 2020, addressing the gap in national data on healthcare-associated infections, using information from a private laboratory network.

Methods: A cross-sectional study was conducted using a database from Fleury hospital network, a private laboratory in Brazil. The analysis included blood, urine, and lower respiratory tract samples collected from January 2018 to June 2020.

View Article and Find Full Text PDF

To evaluate the real-world evidence of ceftazidime-avibactam (CAZ-AVI) compared to intravenous colistin for the treatment of multidrug-resistant (MDR) infections. This is a multicenter, retrospective cohort study conducted in the period between 2017 and 2023 at five institutions for patients who received either CAZ-AVI or colistin-based regimens for treating MDR infections. Outcomes were compared using multivariate logistic regression analysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!